The asymmetric unit of the title compound, C(18)H(16)F(4)N(2), comprises two half crystallographically independent potentially bidentate Schiff base ligands, with an inversion centre located at the mid-point of the central C-C bond. The crystal packing is stabilized by inter-molecular C-H⋯F and π-π inter-actions [centroid-centroid distance = 3.8283 (11) Å].

In the title mononuclear complex, [Co(C(12)H(17)N(2)OS(2))(2)], the Co(II) atom is four-coordinated by two N,O-bidentate Schiff base ligands, resulting in a slightly distorted trans-CoN(2)O(2) square-planar coordination.

In the title mononuclear copper(II) complex, [Cu(C(7)H(5)ClNO)(2)], the Cu atom, situated on an inversion center, is four-coordinated, in a slightly distorted square-planar geometry, by the N- and O-donor atoms of two symmetry-related 4-chloro-2-(imino-meth-yl)phenolate Schiff base ligands.

In the title complex, [Co(C(15)H(12)Br(2)NO)(2)], the Co(II) atom is four-coordinated by two N,O-bidentate chelate Schiff base ligands, displaying a flattened tetra-hedral coordination environment. The Co(II) atom occupies a special position on a twofold rotation axis. In the crystal, mol-ecules are linked via weak C-H⋯Br inter-actions.

The centrosymmetric title complex, [Ni(C(13)H(19)N(2)O(2))(2)], is a mononuclear nickel(II) complex. The Ni(II) atom is coordinated by four N atoms and two O atoms of two deprotonated Schiff base ligands, forming a slightly distorted octa-hedral coordination configuration, in which the tertiary N atoms occupy the axial positions.

The Zn atom in the title compound, [Zn(C(17)H(14)ClN(2)O)(2)], is N,O-chelated by two deprotonated Schiff base monoanionic ligands in a tetra-hedral coordination geometry. The Zn atom lies on a special position of site symmetry 2.

In the title complex, [Zn(C(11)H(12)NO(2))(2)], the Zn(2+) ion (site symmetry 2) is coordinated by two N,O-bidentate Schiff base ligands, generating a tetra-hedral ZnO(2)N(2) geometry for the metal ion.

Encapsulation of the anticancer gold(III) complexes bearing porphyrin or Schiff-base ligands by gelatin-acacia microcapsules confers both sustained-release and rapid-release properties, improved solution stability and/or in vivo efficacy compared to that using the unencapsulated complexes alone.

Little is known about the molecular mechanism of Schiff base hydrolysis in rhodopsin. We report here our investigation into this process focusing on the role of amino acids involved in a hydrogen bond network around the retinal Schiff base. We find conservative mutations in this network (T94I, E113Q, S186A, E181Q, Y192F, and Y268F) increase the activation energy (E(a)) and abolish the concave A...

Some new symmetrical tetraaza Schiff base ligands containing 2-quinolinecarboxaldehyde moiety formed from condensation reaction of 2-quinolinecarboxaldehyde and o-phenylenediamine derivatives, such as N, Nˊ-bis(2-quinolylmethylidene)-4-methoxy-1, 2-phenylenediimine (L1), N, Nˊ-bis(2-quinolylmethylidene)-4-methy-1, 2-phenylenediimine (L2), N, Nˊ-bis(2-quinolylmethylidene)-4-chloro-1, 2-phenylene...